EIF4ENIF1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-engineered loss-of-function model targeting the EIF4ENIF1 gene, which encodes the eIF4E-binding protein 4E-T. Supplied as a polyclonal knockout cell population derived from HeLa cells, this product provides a heterogeneous pool of edited cells suitable for studying translational control in the absence of functional 4E-T expression. The targeted gene disruption was achieved using CRISPR/Cas9, eliminating the need for clonal selection and enabling rapid experimental deployment.
HeLa cells are an immortalized human cervical adenocarcinoma line established in 1951 from a cervical carcinoma. Widely used across biomedical research, this cell line offers a well-characterized model system for investigating cancer biology, gene expression, and signal transduction. Its robust growth characteristics, high transfectability, and extensive molecular annotation facilitate the generation and analysis of CRISPR/Cas9-mediated knockouts.
EIF4ENIF1 (4E-T) functions as a translational repressor by binding eIF4E and directing associated mRNAs to processing bodies (P-bodies) for decay or storage. Its activity is regulated by upstream mTOR signaling and cellular stress, and it interacts with P-body components including LSM14A, DDX6, PATL1, and DCP1A. Key downstream targets of eIF4E-sensitive translation include CCND1, MYC, and VEGFA, which drive cell cycle progression, proliferation, and angiogenesis.
In the HeLa cervical carcinoma context, EIF4ENIF1 knockout relieves translational repression on eIF4E-dependent mRNAs, elevating synthesis of proteins that promote oncogenic phenotypes. This disruption likely perturbs P-body dynamics and mRNA turnover, offering a valuable model to explore the interplay between translation control and cancer cell behavior. Since translation dysregulation is a cancer hallmark, these cells help dissect how 4E-T loss affects gene expression programs involved in growth and stress responses.
Typical applications include Western blotting and immunoprecipitation to confirm 4E-T absence and altered eIF4E complexes, polysome profiling and RNA-seq for translational landscape analysis, and immunofluorescence for P-body markers (e.g., DCP1A). Luciferase reporter assays with cap-dependent constructs quantify translational output, and cell proliferation assays reveal functional consequences. These tools support research into cap-dependent translation, mRNA decay pathways, and screening of translation inhibitors. For further details, please contact Ascent Research.
